# Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion

> **NCT04882358** · NA · UNKNOWN · sponsor: **Sequana Medical N.V.** · enrollment: 24 (estimated)

## Conditions studied

- Heart Failure
- Volume Overload

## Interventions

- **DEVICE:** ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT04882358
- **Lead sponsor:** Sequana Medical N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-27
- **Primary completion:** 2022-08-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882358, "Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04882358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*